BACKGROUND: Amphetamine-type stimulants (ATS) are globally widely used. Scientific literature generally defines four phases of substance use (initiation, continuation, increase and decrease); however, there is limited understanding of what influences these different phases of ATS use. The ATTUNE study investigated which factors shape individual phases of use, or ATS use patterns. In this article, we report on these phases into and out of ATS use, and propose a set of recommendations for prevention, harm reduction and treatment of the different phases of ATS use. METHODS: Qualitative, semi-structured interviews (n = 237) were conducted in five different European countries with participants who had used ATS, varying from a few times in a lifetime to daily. RESULTS: Amphetamine and MDMA were the most commonly used ATS. Yet, types of ATS used differed between the countries. We found that people who use ATS have various motives for and dynamic patterns of ATS use with alternating phases of increase, continuation, decrease and sometimes dependence. Cessation was pursued in different ways and for diverse reasons, such as mental health problems and maturing out. Availability seemed not an issue, regardless of the type of ATS, phase or country. CONCLUSIONS: These findings demonstrate that tailor-made interventions are needed for the diverse types of people who use ATS and different phases or patterns of ATS use, to reduce possible harms of use. We recommended a set of interventions for the different ATS phases. These include drug checking services, peer-led information, self-management of ATS use, mental health support to help people cope with stressful life events and prevent uncontrolled use, and follow-up support after treatment.

Bonger Institute of Criminology University of Amsterdam Amsterdam The Netherlands

Centre of Interdisciplinary Addiction Research of Hamburg University Department of Psychiatry University Medical Centre Hamburg Eppendorf Hamburg Germany

Correlation European Harm Reduction Network Amsterdam The Netherlands

Department of Addictology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Psychology Maria Grzegorzewska University Warsaw Poland

Zobrazit více v PubMed

EMCDDA . European drug report 2020: trends and developments. Luxembourg: Publications Office of the European Union; 2020.

United Nations. World drug report 2020. 2020. https://wdr.unodc.org/wdr2020/.

O’Donnell A, Addison M, Spencer L, Zurhold H, Rosenkranz M, McGovern R, Gilvarry E, Martens MS, Verthein U, Kaner E. Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature. Addiction. 2019;114(1):24–47. doi: 10.1111/add.14434. PubMed DOI PMC

Duff C, Moore D. Evading and embracing normality: estrangement and ambivalence in the accounts of methamphetamine consumers. Crit Public Health. 2015;25(4):488–503. doi: 10.1080/09581596.2014.913785. DOI

Levy KB, O’Grady KE, Wish ED, Arria AM. An in-depth qualitative examination of the ecstasy experience: results of a focus group with ecstasy-using college students. Subst Use Misuse. 2005;40(9–10):1427–1441. doi: 10.1081/JA-200066810. PubMed DOI PMC

Van Hout MC, Brennan R. Plant food for thought: a qualitative study of mephedrone use in Ireland. Drugs Educ Prev Policy. 2011;18(5):371–381. doi: 10.3109/09687637.2010.537713. DOI

Boeri MW, Harbry L, Gibson D. A qualitative exploration of trajectories among suburban users of methamphetamine. J Ethnogr Qual Res. 2009;3(3):139–151. PubMed PMC

Boeri MW, Sterk CE, Elifson KW. Baby boomer drug users: career phases, social control, and social learning theory*. Sociol Inq. 2006;76(2):264–291. doi: 10.1111/j.1475-682X.2006.00154.x. DOI

Ho HT, Le GM, Dinh TT. Female sex workers who use amphetamine-type stimulants (ATS) in three cities of Vietnam: use and sexual risks related to HIV/AIDS. Glob Public Health. 2013;8(5):552–569. doi: 10.1080/17441692.2013.790459. PubMed DOI

Ding Y, He N, Detels R. Circumstances of initiation into new-type drug use among adults in Shanghai: Are there differences by types of first new-type drug used? Drug Alcohol Depend. 2013;131(3):278–283. doi: 10.1016/j.drugalcdep.2012.12.019. PubMed DOI PMC

Eiserman JM, Diamond S, Schensul JJ. Rollin’’ on E": a qualitative analysis of ecstasy use among inner city adolescents and young adults. J Ethn Subst Abuse. 2005;4(2):9–38. doi: 10.1300/J233v04n02_02. PubMed DOI

Cheney AM, Newkirk CN, Nekhavhambe VM, Rotondi MB, Hamilton A. Effects of social and spatial contexts on young latinas’ methamphetamine use initiation. J Ethn Subst Abuse. 2018;17(1):32–49. doi: 10.1080/15332640.2017.1362721. PubMed DOI PMC

Fast D, Small W, Wood E, Kerr T. Coming “down here”: young people’s reflections on becoming entrenched in a local drug scene. Soc Sci Med. 2009;69(8):1204–1210. doi: 10.1016/j.socscimed.2009.07.024. PubMed DOI PMC

Smirnov A, Najman JM, Hayatbakhsh R, Wells H, Legosz M, Kemp R. Young adults’ recreational social environment as a predictor of ecstasy use initiation: findings of a population-based prospective study. Addiction. 2013;108(10):1809–1817. doi: 10.1111/add.12239. PubMed DOI

Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC. Risk and protective factors for methamphetamine use and nonmedical use of prescription stimulants among young adults aged 18 to 25. Addict Behav. 2007;32(5):1003–1015. doi: 10.1016/j.addbeh.2006.07.010. PubMed DOI

Bavarian N, Flay BR, Ketcham PL, Smit E. Illicit use of prescription stimulants in a college student sample: a theory-guided analysis. Drug Alcohol Depend. 2013;132(3):665–673. doi: 10.1016/j.drugalcdep.2013.04.024. PubMed DOI PMC

Carbone-Lopez K, Owens JG, Miller J. Women’s “storylines” of methamphetamine initiation in the midwest. J Drug Issues. 2012;42(3):226–246. doi: 10.1177/0022042612456013. DOI

Kerley KR, Leban L, Copes H, Taylor L, Agnone C. Methamphetamine using careers of white and black women. Deviant Behav. 2014;35(6):477–495. doi: 10.1080/01639625.2013.859046. DOI

Sterk CE, Theall KP, Elifson KW. Getting Into ecstasy: comparing moderate and heavy young adult users. J Psychoact Drugs. 2007;39(2):103–113. doi: 10.1080/02791072.2007.10399869. PubMed DOI

Bungay V, Malchy L, Buxton JA, Johnson J, MacPherson D, Rosenfeld T. Life with jib: a snapshot of street youth’s use of crystal methamphetamine. Addict Res Theory. 2006;14(3):235–251. doi: 10.1080/16066350500270901. DOI

Bourne A, Reid D, Hickson F, Torres-Rueda S, Steinberg P, Weatherburn P. “Chemsex” and harm reduction need among gay men in South London. Int J Drug Policy. 2015;26(12):1171–1176. doi: 10.1016/j.drugpo.2015.07.013. PubMed DOI

O’Brien AM, Brecht ML, Casey C. Narratives of methamphetamine abuse: a qualitative exploration of social, psychological, and emotional experiences. J Soc Work Pract Addict. 2008;8(3):343–366. doi: 10.1080/15332560802224469. DOI

Sexton RL, Carlson RG, Leukefeld CG, Booth BM. Trajectories of methamphetamine use in the rural south: a longitudinal qualitative study. Hum Organ. 2008;67(2):181–193. doi: 10.17730/humo.67.2.h457132482255391. DOI

Hearne E, Grund J-PC, Van Hout MC, McVeigh J. A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy. Harm Reduct J. 2016;13(1):14. doi: 10.1186/s12954-016-0105-2. PubMed DOI PMC

Hunter C, Strike C, Barnaby L, Busch A, Marshall C, Shepherd S, Hopkins S. Reducing widespread pipe sharing and risky sex among crystal methamphetamine smokers in Toronto: Do safer smoking kits have a potential role to play? Harm Reduct J. 2012;9(1):9. doi: 10.1186/1477-7517-9-9. PubMed DOI PMC

Zweben J, Cohen J, Christian D, Pharm GG, Salinardi M, Parent D, Iguchi M. Psychiatric symptoms in methamphetamine users. Am J Addict. 2010;13(2):181–190. doi: 10.1080/10550490490436055. PubMed DOI

Grund J-P, Coffin P, Jauffret-roustide M, Dijkstra M, de Bruin D, Blanken P. The fast and furious—cocaine, amphetamines and harm reduction. In: Rhodes T, Hedrich D, editors. Harm reduction: evidence, impacts and challenges (EMCDDA Mon) Luxembourg: Publications Office of the European Union; 2010. pp. 191–232.

Degenhardt L, Baxter AJ, Lee YY, Hall W, Sara GE, Johns N, Flaxman A, Whiteford HA, Vos T. The global epidemiology and burden of psychostimulant dependence: findings from the global burden of disease study 2010. Drug Alcohol Depend. 2014;137(1):36–47. doi: 10.1016/j.drugalcdep.2013.12.025. PubMed DOI

Fisher AH, Stanciu CN. Amphetamine-induced delusional infestation. Am J Psychiatry Resid J. 2017 doi: 10.1176/appi.ajp-rj.2017.121204. DOI

Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M, Shoptaw S, McKetin R. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394(10209):1652–1667. doi: 10.1016/S0140-6736(19)32230-5. PubMed DOI PMC

Harm Reduction International. The global state of harm reduction 2020. 2020. https://www.hri.global/files/2020/10/26/Global_State_HRI_2020_BOOK_FA.pdf

WHO . Technical Briefs 2 on amphetamine-type stimulants (ATS). Harm reduction and brief interventions for ATS users. Genava: WHO; 2011.

Rigoni R, Woods S, Breeksema JJ. From opiates to methamphetamine: building new harm reduction responses in Jakarta, Indonesia. Harm Reduct J. 2019;16(1):67. doi: 10.1186/s12954-019-0341-3. PubMed DOI PMC

Rosenkranz M, O’Donnell A, Verthein U, Zurhold H, Addison M, Liebregts N, Rowicka M, Barták M, Petruželka B, Kaner EF, Martens MS. Understanding pathways to stimulant use: a mixed-methods examination of the individual, social and cultural factors shaping illicit stimulant use across Europe (ATTUNE): study protocol. BMJ Open. 2019;9(8):e029476. doi: 10.1136/bmjopen-2019-029476. PubMed DOI PMC

Liebregts N, van der Pol P, Van Laar M, de Graaf R, van den Brink W, Korf DJ. The role of study and work in cannabis use and dependence trajectories among young adult frequent cannabis users. Front Psychiatry. 2013;4(8):85. doi: 10.3389/fpsyt.2013.00085. PubMed DOI PMC

Nichter M, Quintero G, Nichter M, Mock J, Shakib S. Qualitative research: contributions to the study of drug use, drug abuse, and drug use(r)-related interventions. Subst Use Misuse. 2004;39(10–12):1907–1969. doi: 10.1081/JA-200033233. PubMed DOI

Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J. The severity of dependence scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction. 1995;90(5):607–614. doi: 10.1046/j.1360-0443.1995.9056072.x. PubMed DOI

Bruno R, Matthews AJ, Topp L, Degenhardt L, Gomez R, Dunn M. Can the severity of dependence scale be usefully applied to ‘ecstasy’’?’. Neuropsychobiology. 2009;60(3–4):137–147. doi: 10.1159/000253550. PubMed DOI

Liebregts N. Nuts and bolts of timelines in qualitative drug research. In: Potter GJ, Fountain J, Korf DJ, editors. Place, space and time in European drug use, markets and policy. Lengerich: Pabst Science Publishers; 2018.

Martens MS, Zurhold H, Rosenkranz M, O’donnell A, Addison M, Spencer L, McGovern W, Gabrhelík R, Petruželka B, Rowicka M, Liebregts N, Degkwitz P, Kaner E, Verthein U. Using life course charts to assess and compare trajectories of amphetamine type stimulant consumption in different user groups: a cross-sectional study. Harm Reduct J. 2020 doi: 10.1186/s12954-019-0339-x. PubMed DOI PMC

Rigg KK. Motivations for using MDMA (Ecstasy/Molly) among African Americans: implications for prevention and harm-reduction programs. J Psychoact Drugs. 2017;49(3):192–200. doi: 10.1080/02791072.2017.1305518. PubMed DOI

Kinner SA, George J, Johnston J, Dunn M, Degenhardt L. Pills and pints: risky drinking and alcohol-related harms among regular ecstasy users in Australia. Drug Alcohol Rev. 2012;31(3):273–280. doi: 10.1111/j.1465-3362.2011.00348.x. PubMed DOI

Rigg KK, Lawental M. perceived risk associated with MDMA (ecstasy/molly) use among African Americans: what prevention and treatment providers should know. Subst Use Misuse. 2018;53(7):1076–1083. doi: 10.1080/10826084.2017.1392985. PubMed DOI

Docherty JR, Green AR. The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol. 2010;160(5):1029–1044. doi: 10.1111/j.1476-5381.2010.00722.x. PubMed DOI PMC

Champion KE, Newton NC, Stapinski L, Teesson M. Cluster randomised controlled trial of an online intervention to prevent ecstasy and new psychoactive substance use among adolescents: final results and implications for implementation. BMJ Open. 2018;8(11):433. doi: 10.1136/bmjopen-2017-020433. PubMed DOI PMC

Korf DJ, Riper H, Freeman M, Lewis R, Grant I, Jacob E, Mougin C, Nilson M. Outreach work among drug users in Europe: concepts, practice and terminology. Luxembourg: Office for Official Publications of the European Communities; 1999.

Imtiaz S, Strike C, Elton-Marshall T, Rehm J. Safer smoking kits for methamphetamine consumption. Addiction. 2020;115(6):1189–1190. doi: 10.1111/add.14914. PubMed DOI

Silins E, Bleeker AM, Simpson M, Dillon P, Copeland J. Does peer-delivered information at music events reduce ecstasy and methamphetamine use at three month follow-up. Findings from a quasi-experiment across three study sites. J Addict Prev. 2014;2(1):1–8.

Jenner L, Lee N. Treatment approaches for users of methamphetamine: a practical guide for frontline workers. 2008.

Elifson KW, Klein H, Sterk CE. Young adult ecstasy users who forego necessary medical care: a fairly common occurrence with important health implications. J Psychoact Drugs. 2010;42(1):63–71. doi: 10.1080/02791072.2010.10399786. PubMed DOI PMC

MacLean S, Harney A, Arabena K. Primary health-care responses to methamphetamine use in Australian Indigenous communities. Aust J Primary Health. 2015;21(4):384–390. doi: 10.1071/PY14126. PubMed DOI

Powelson E, Lorvick J, Lutnick A, Wenger L, Klausner J, Kral AH. Unmet healthcare need among women who use methamphetamine in San Francisco. Subst Use Misuse. 2014;49(3):243–252. doi: 10.3109/10826084.2013.825919. PubMed DOI

Zinberg NE. Drug, set, and setting. The basis for controlled intoxicant use. New Haven: Yale University Press; 1984.

Chavarria J, Stevens EB, Jason LA, Ferrari JR. The effects of self-regulation and self-efficacy on substance use abstinence. Alcohol Treat Q. 2012;30(4):422–432. doi: 10.1111/j.1743-6109.2008.01122.x.Endothelial. PubMed DOI PMC

Ferrari JR, Stevens EB, Jason LA. The role of self-regulation in abstinence maintenance: effects of communal living on self-regulation. J Groups Addict Recov. 2009;4(1–2):32–41. doi: 10.1080/15560350802712371. PubMed DOI PMC

Rigoni R, Breeksema J, Woods S. Speed limits. Harm reduction for people who use stimulants. Amsterdam: Mainline Foundation; 2018.

Zuffa G, Ronconi S. Cocaine and stimulants, the challenge of self-regulation in a harm reduction perspective. Epidemiol Biostat Public Health. 2015;12(1):e-1–e-8. doi: 10.2427/11175. DOI

Scott RM, Hides L, Allen JS, Lubman DI. Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users. Addict Behav. 2013;38(10):2465–2472. doi: 10.1016/j.addbeh.2013.05.005. PubMed DOI

Brunt TM, Niesink RJM. The drug information and monitoring system (DIMS) in the Netherlands: implementation, results, and international comparison. Drug Test Anal. 2011;3(9):621–634. doi: 10.1002/dta.323. PubMed DOI

Davies N, English W, Grundlingh J. MDMA toxicity: management of acute and life-threatening presentations. Br J Nurs. 2018;27(11):616–622. doi: 10.12968/bjon.2018.27.11.616. PubMed DOI

Transform. How to regulate Stimulants. A practical guide. 2020.

UNODC. Treatment of Stimulant use disorders: current practices and promising perspectives. Discussion paper. United Nations Office on Drugs and Crime (UNODC). 2019.

Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, Kansagara D. Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta-analysis. Addiction. 2019;114(12):2122–36. 10.1111/add.14755. PubMed

Miles SW, Sheridan J, Russell B, Kydd R, Wheeler A, Walters C, Gamble G, Hardley P, Jensen M, Kuoppasalmi K, Tuomola P, FöhrJ, Kuikanmäki O, Vorma H, Salokangas R, Mikkonen A, Kallio M, Kauhanen J, Kiviniemi V, Tiihonen J. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized double-blind placebo-controlled trial. Addiction. 2013;108(7):1279–86. 10.1111/add.12109. PubMed

Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, Santos D, Colfax G, Batki SL. Effects of Mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men. JAMA Psychiatry. 2020;77(3):246–55. 10.1001/jamapsychiatry.2019.3655. PubMed PMC

Lee NK, Jenner L, Harney A, Cameron J. Pharmacotherapy for amphetamine dependence: a systematic review. Drug Alcohol Depend. 2018;191:309–337. doi: 10.1016/j.drugalcdep.2018.06.038. PubMed DOI

Minařík J, Gabrhelík R, Malcolm R, Pavlovská A, Miller P. Methylphenidate substitution for methamphetamine addiction and implications for future randomized clinical trials: a unique case series. J Subst Use. 2016;21(4):435–438. doi: 10.3109/14659891.2015.1045047. DOI

Magidson JF, Gouse H, Burnhams W, Wu CYY, Myers B, Joska JA, Carrico AW. Beyond methamphetamine: documenting the implementation of the matrix model of substance use treatment for opioid users in a South African setting. Addict Behav. 2017;66:132–137. doi: 10.1016/j.addbeh.2016.11.014. PubMed DOI PMC

Baker A, Lee N, Claire M, Lewin T. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction. 2005;100:367–378. doi: 10.1111/j.1360-0443.2005.001002.x. PubMed DOI

Norberg MM, Hides L, Olivier J, Khawar L, McKetin R, Copeland J. Brief interventions to reduce Ecstasy use: a multi-site randomized controlled trial. Behav Ther. 2014;45(6):745–759. doi: 10.1016/j.beth.2014.05.006. PubMed DOI

Huang Y-S, Tang T-C, Lin C-H, Yen C-F. Effects of motivational enhancement therapy on readiness to change MDMA and methamphetamine use behaviors in Taiwanese adolescents. Subst Use Misuse. 2011;46(4):411–416. doi: 10.3109/10826084.2010.501664. PubMed DOI

McKetin R, Dunlop AJ, Holland RM, Sutherland RA, Baker AL, Salmon AM, Hudson SL. Treatment outcomes for methamphetamine users receiving outpatient counselling from the stimulant treatment program in Australia. Drug Alcohol Rev. 2013;32(1):80–87. doi: 10.1111/j.1465-3362.2012.00471.x. PubMed DOI

Risk-sharing agreements for medical devices: a stakeholder-based qualitative study in Czechia